Immunologic control of cancer stem cells, dormancy
Hematopoietic, immune system, skin, others
HSCs, cancer stem cells, others
Solid tumor oncology specifically skin, sarcoma, and GU; hematologic malignancies
Focus Groups: Cancer Stem Cells; Immunomodulatory Therapies; Integumentary;
Research description: Translational/Clinical
Clinical trials of immunotherapy, animal models of combination/sequencing immunotherapy, immune markers in micrometastatic/dormancy states.
Technical expertise: clinical management of cancers and blood disorders, stem cell transplantation, animal models of immunotherapy
- Novel approaches in cancer immunotherapy — a light at the end of the tunnel. Joshi M, Pal SK, Drabick JJ. Discov Med. 2016 Jun;21(118):479-87.
- Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.Wyluda EJ, Cheng J, Schell TD, Haley JS, Mallon C, Neves RI, Robertson G, Sivik J, Mackley H, Talamo G, Drabick JJ. Cancer Biol Ther. 2015;16(5):662-70.